Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct;58(10):1666-1671.
doi: 10.2967/jnumed.117.192252. Epub 2017 Apr 6.

18F-Tetrafluoroborate, a PET Probe for Imaging Sodium/Iodide Symporter Expression: Whole-Body Biodistribution, Safety, and Radiation Dosimetry in Thyroid Cancer Patients

Affiliations

18F-Tetrafluoroborate, a PET Probe for Imaging Sodium/Iodide Symporter Expression: Whole-Body Biodistribution, Safety, and Radiation Dosimetry in Thyroid Cancer Patients

Jim O'Doherty et al. J Nucl Med. 2017 Oct.

Abstract

We report the safety, biodistribution, and internal radiation dosimetry, in humans with thyroid cancer, of 18F-tetrafluoroborate (18F-TFB), a novel PET radioligand for imaging the human sodium/iodide symporter (hNIS). Methods: Serial whole-body PET scans of 5 subjects with recently diagnosed thyroid cancer were acquired before surgery for up to 4 h after injection of 184 ± 15 MBq of 18F-TFB. Activity was determined in whole blood, plasma, and urine. Mean organ-absorbed doses and effective doses were calculated via quantitative image analysis and using OLINDA/EXM software. Results: Images showed a high uptake of 18F-TFB in known areas of high hNIS expression (thyroid, salivary glands, and stomach). Excretion was predominantly renal. No adverse effects in relation to safety of the radiopharmaceutical were observed. The effective dose was 0.0326 ± 0.0018 mSv/MBq. The critical tissues/organs receiving the highest mean sex-averaged absorbed doses were the thyroid (0.135 ± 0.079 mSv/MBq), stomach (0.069 ± 0.022 mSv/MBq), and salivary glands (parotids, 0.031 ± 0.011 mSv/MBq; submandibular, 0.061 ± 0.031 mSv/MBq). Other organs of interest were the bladder (0.102 ± 0.046 mSv/MBq) and kidneys (0.029 ± 0.009 mSv/MBq). Conclusion: Imaging using 18F-TFB imparts a radiation exposure similar in magnitude to many other 18F-labeled radiotracers. 18F-TFB shows a biodistribution similar to 99mTc-pertechnetate, a known nonorganified hNIS tracer, and is pharmacologically and radiobiologically safe in humans. Phase 2 trials for 18F-TFB as an hNIS imaging agent are warranted.

Keywords: 18F-TFB; PET/CT; thyroid imaging.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Imaging scan schedule for the whole-body dynamic PET-CT study (not to scale). Dots above the scan positions show the timings of venous blood sampling and squares represent nominal urine sampling times.
Figure 2
Figure 2
Decay-corrected serial maximum-intensity projections showing the biodistribution of 18F-TFB over the course of the imaging study. Thyroid, salivary gland and stomach activities increase rapidly with time up to 30 minutes. Image captioned t = 0-9 min represents the first imaging frame.
Figure 3
Figure 3
Percentage of injected dose per gram of tissue (%ID/g) curves for selected organs, averaged over all 5 patients. Large standard deviations are evident in the hNIS expressing tissues and organs
Figure 4
Figure 4
Top - Mean decay-corrected blood and plasma curves averaged over all 5 patients. Bottom - mean blood cells to plasma distribution ratio, showing that equilibrium is reached after approximately 30 minutes. Error bars in both plots represent 1 standard deviation of the mean.

References

    1. Chung J-K. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med. 2010;43:1188–1200. - PubMed
    1. Silberstein EB, Alavi A, Balon HR, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med. 2012;53:1633–1651. - PubMed
    1. Phan HT, Jager PL, Paans AM, et al. The diagnostic value of 124I-PET in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:958–965. - PMC - PubMed
    1. Gulec SA, Kuker RA, Goryawala M, et al. 124I PET/CT in patients with differentiated thyroid cancer: Clinical and quantitative image analysis. Thyroid. 2016;26:441–448. - PubMed
    1. Woods DH, Woods SA, Woods MJ, et al. The standardization and measurement of decay scheme data of 124I. Int J Radiat Appl Instrum Part A Appl Radiat Isot. 1992;43:551–560.

Publication types

LinkOut - more resources